NASH
Clinical trials for NASH explained in plain language.
Never miss a new study
Get alerted when new NASH trials appear
Sign up with your email to follow new studies for NASH, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old heart drug could be new hope against fatty liver
Disease control Recruiting nowThis study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). The trial will involve 144 adults with biopsy-confirmed NASH and liver scarring. Participants will …
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill aims to melt liver fat in NASH patients
Disease control Recruiting nowThis study tests a new tablet called CS060380 for adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 120 participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track a…
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Hormone link to fatty liver in young women under microscope
Knowledge-focused Recruiting nowThis study looks at how androgens (a type of sex hormone) might affect fatty liver disease in young women. Researchers will compare changes in liver fat and stiffness over time in 150 women with and without PCOS. The goal is to understand the connection, not to test a treatment.
Matched conditions: NASH
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Can genes predict liver cancer in fatty liver patients?
Knowledge-focused Recruiting nowThis study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …
Matched conditions: NASH
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New NASH drug candidate BAR502 enters first human safety trial
Knowledge-focused Recruiting nowThis is the first time BAR502, an experimental drug for NASH (a serious liver condition), is being tested in humans. The study involves 52 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive either a single dose or multiple…
Matched conditions: NASH
Phase: PHASE1 • Sponsor: BAR Pharmaceuticals s.r.l. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC